KDM7A抗体;KDM7A Antibody—艾普蒂 新品

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P13658(KDM7A Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P13658(KDM7A Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

The KDM7A antibody is a crucial tool for studying the lysine demethylase 7A (KDM7A), also known as JHDM1D or KIAA1718. Belonging to the JmjC domain-containing histone demethylase family, KDM7A specifically removes methyl groups from histone H3 lysine 9 (H3K9me2/me1) and lysine 27 (H3K27me2/me1), modulating chromatin structure and gene expression. This enzyme plays roles in embryonic development, cell differentiation, and neural function by regulating epigenetic marks linked to transcriptional activation. Dysregulation of KDM7A is implicated in intellectual disabilities, cancer, and neurodevelopmental disorders.

The KDM7A antibody enables researchers to detect and quantify protein expression, assess subcellular localization (primarily nuclear), and investigate its interaction with chromatin or other regulatory proteins. It is widely used in techniques like Western blotting, immunohistochemistry, immunoprecipitation, and immunofluorescence. Validated antibodies are essential to ensure specificity, as cross-reactivity with related demethylases (e.g., KDM7B/C) can occur. Commercial KDM7A antibodies are typically raised against peptide sequences unique to its catalytic JmjC domain or C-terminal regions. Recent studies also utilize these antibodies to explore KDM7A's non-histone substrates and its potential as a therapeutic target in diseases involving epigenetic dysfunction.